Read by QxMD icon Read

fish for breast disease

Pat Whitworth, Peter Beitsch, Angela Mislowsky, James V Pellicane, Charles Nash, Mary Murray, Laura A Lee, Carrie L Dul, Michael Rotkis, Paul Baron, Lisette Stork-Sloots, Femke A de Snoo, Jennifer Beatty
PURPOSE: Hormone receptor-positive (HR+) tumors have heterogeneous biology and present a challenge for determining optimal treatment. In the Neoadjuvant Breast Registry Symphony Trial (NBRST) patients were classified according to MammaPrint/BluePrint subtyping to provide insight into the response to neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NCT). OBJECTIVE: The purpose of this predefined substudy was to compare MammaPrint/BluePrint with conventional 'clinical' immunohistochemistry/fluorescence in situ hybridization (IHC/FISH) subtyping in 'clinical luminal' [HR+/human epidermal growth factor receptor 2-negative (HER2-)] breast cancer patients to predict treatment sensitivity...
October 21, 2016: Annals of Surgical Oncology
Shailaja Shukla, Bhawana Komal Singh, Om Prakash Pathania, Manjula Jain
BACKGROUND & OBJECTIVES: The proto-oncogene HER2/neu has been extensively studied in breast cancer patients. Serum levels of HER2/neu by ELISA in breast cancer patients were compared with tissue HER2/neu expression and with other clinicopathological parameters with the aim to investigate whether the serum assay could replace the established tests (IHC/FISH) for HER-2 status. METHODS: Blood and Tru-cut biopsy samples were collected for determining HER2/neu status in 64 breast cancer patients...
May 2016: Indian Journal of Medical Research
Manjima Dhar, Edward Pao, Corinne Renier, Derek E Go, James Che, Rosita Montoya, Rachel Conrad, Melissa Matsumoto, Kyra Heirich, Melanie Triboulet, Jianyu Rao, Stefanie S Jeffrey, Edward B Garon, Jonathan Goldman, Nagesh P Rao, Rajan Kulkarni, Elodie Sollier-Christen, Dino Di Carlo
Circulating tumor cells (CTCs) have a great potential as indicators of metastatic disease that may help physicians improve cancer prognostication, treatment and patient outcomes. Heterogeneous marker expression as well as the complexity of current antibody-based isolation and analysis systems highlights the need for alternative methods. In this work, we use a microfluidic Vortex device that can selectively isolate potential tumor cells from blood independent of cell surface expression. This system was adapted to interface with three protein-marker-free analysis techniques: (i) an in-flow automated image processing system to enumerate cells released, (ii) cytological analysis using Papanicolaou (Pap) staining and (iii) fluorescence in situ hybridization (FISH) targeting the ALK rearrangement...
October 14, 2016: Scientific Reports
Diogo Morbeck, Aline Caldart Tregnago, Glauco Baiocchi Netto, Carlos Sacomani, Patricia Maria Peresi, Cynthia Toledo Osório, Luciana Schutz, Stephania Martins Bezerra, Louise de Brot, Isabela Werneck Cunha
AIMS: GATA3 has been reported as a specific urothelial marker among organs in the pelvic region and has been classified as highly sensitive and specific for urothelial and breast carcinomas. Our aim was to verify GATA3 expression in extramammary Paget disease (EMPD) and check if it can be use to differentiate primary vulvar Paget disease (PVPD) from pagetoid urothelial intraepithelial neoplasia (PUIN). Also we analyzed Her2 protein expression and HER2 gene amplification and its role as prognostic factors in EMPD METHODS AND RESULTS: We analyzed GATA3 and Her2 expression in 11 primary vulvar Paget disease and also 2 PUIN cases...
September 16, 2016: Histopathology
John D Hainsworth, Patrick B Murphy, Jose R Alemar, Brooke R Daniel, Robyn R Young, Denise A Yardley
PURPOSE: Determination of HER2 status by testing circulating tumor cells (CTCs), compared to sampling tumor biopsies, may improve patient management by allowing ongoing assessment of HER2 status during the disease course. The PRO Onc assay (Prometheus Laboratories; San Diego, CA) is a multiplexed immunoassay that measures the expression and activation of HER2 in CTCs. In this study, we screened patients with metastatic HER2-negative breast cancer with the PRO Onc assay; patients with HER2 overexpression or activation received a trial of HER2-targeted therapy...
November 2016: Breast Cancer Research and Treatment
Hee Young Na, Ji-Young Choe, Seon Ah Shin, Ho-Kyung Choung, Sohee Oh, Jin-Haeng Chung, Mira Park, Ji Eun Kim
Despite recent progress in comprehensive genetic analysis, little is known about the molecular pathogenesis of sebaceous carcinoma. On the basis of the ontogenic proximity of sebaceous and mammary glands, we designed an intrinsic classification for sebaceous carcinoma adapted from that of breast cancer and evaluated its clinical significance. We investigated 42 cases of sebaceous carcinoma, including 32 ocular and 10 extraocular cases. Immunohistochemical analyses for estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), HER2, Ki67, and CK5/6 and fluorescence in situ hybridization for the HER2 gene were performed...
September 14, 2016: American Journal of Surgical Pathology
Federica Turdo, Francesca Bianchi, Patrizia Gasparini, Marco Sandri, Marianna Sasso, Loris De Cecco, Luca Forte, Patrizia Casalini, Piera Aiello, Lucia Sfondrini, Roberto Agresti, Maria Luisa Carcangiu, Ilaria Plantamura, Gabriella Sozzi, Elda Tagliabue, Manuela Campiglio
CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities-ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH)...
September 10, 2016: Oncotarget
Elizabeth A Mittendorf, Alexandros Ardavanis, Jennifer K Litton, Nathan M Shumway, Diane F Hale, James L Murray, Sonia A Perez, Sathibalan Ponniah, Constantin N Baxevanis, Michael Papamichail, George E Peoples
GP2 is a HER2-derived, HLA-A2+ restricted peptide. Phase I studies showed GP2 administered with GM-CSF to be safe and immunogenic. Here we report the primary analysis of a prospective, randomized, multicenter phase II adjuvant trial conducted to determine the vaccine's efficacy. The trial enrolled HLA-A2+, clinically disease-free, node-positive and high-risk node-negative breast cancer patients with tumors expressing HER2 (immunohistochemistry[IHC] 1+-3+). Patients were randomized to GP2+GM-CSF versus GM-CSF alone...
August 31, 2016: Oncotarget
Michael F Press, Guido Sauter, Marc Buyse, Hélène Fourmanoir, Emmanuel Quinaux, Denice D Tsao-Wei, Wolfgang Eiermann, Nicholas Robert, Tadeusz Pienkowski, John Crown, Miguel Martin, Vicente Valero, John R Mackey, Valerie Bee, Yanling Ma, Ivonne Villalobos, Anaamika Campeau, Martina Mirlacher, Mary-Ann Lindsay, Dennis J Slamon
PURPOSE: ASCO and the College of American Pathologists (ASCO-CAP) recently recommended further changes to the evaluation of human epidermal growth factor receptor 2 gene (HER2) amplification by fluorescent in situ hybridization (FISH). We retrospectively assessed the impact of these new guidelines by using annotated Breast Cancer International Research Group (BCIRG) -005, BCIRG-006, and BCIRG-007 clinical trials data for which we have detailed outcomes. PATIENTS AND METHODS: The HER2 FISH status of BCIRG-005/006/007 patients with breast cancers was re-evaluated according to current ASCO-CAP guidelines, which designates five different groups according to HER2 FISH ratio and average HER2 gene copy number per tumor cell: group 1 (in situ hybridization [ISH]-positive): HER2-to-chromosome 17 centromere ratio ≥ 2...
August 29, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Qian-Qian Xu, Bo Pan, Chang-Jun Wang, Yi-Dong Zhou, Feng Mao, Yan Lin, Jing-Hong Guan, Song-Jie Shen, Xiao-Hui Zhang, Ya-Li Xu, Ying Zhong, Xue-Jing Wang, Yan-Na Zhang, Qiang Sun
BACKGROUND: Trastuzumab-based therapy is a standard, targeted treatment for HER2-positive breast cancer in the adjuvant setting. However, patients do not benefit equally from it and the association between HER2 amplification level and patients' survival remains controversial. A systematic review and meta-analysis was conducted by incorporating all available evidence to evaluate the association between disease free survival (DFS) and HER2 amplification level. RESULTS: Three cohort studies involving 1360 HER2-positive breast cancer patients stratified by HER2 amplification magnitude were eligible for meta-analysis...
August 23, 2016: Oncotarget
Humaid O Al-Shamsi, Yazan Fahmawi, Ibrahim Dahbour, Aziz Tabash, Jane E Rogers, Jeannette Elizabeth Mares, Mariela A Blum, Jeannelyn Estrella, Aurelio Matamoros, Tara Sagebiel, Catherine E Devine, Brian D Badgwell, Quan D Lin, Prajnan Das, Jaffer A Ajani
BACKGROUND: Despite the wide spread use of trastuzumab in human epidermal growth factor receptor 2 (HER2) overexpressing metastatic gastric cancer patients, its optimal duration of administration beyond first-line disease progression is unknown. In HER2 overexpressing metastatic breast cancer, trastuzumab continuation beyond first-line disease progression has shown improvement in time to progression (TTP) without an increased risk of treatment related toxicity. METHODS: HER2-overexpressing metastatic gastric cancer patients were identified from our database between January 2010 and December 2014...
August 2016: Journal of Gastrointestinal Oncology
Kyly C Whitfield, Crystal D Karakochuk, Hou Kroeun, Daniela Hampel, Ly Sokhoing, Benny B Chan, Mam Borath, Prak Sophonneary, Judy McLean, Aminuzzaman Talukder, Larry D Lynd, Eunice C Y Li-Chan, David D Kitts, Lindsay H Allen, Timothy J Green
Importance: Infantile beriberi, a potentially fatal disease caused by thiamine deficiency, remains a public health concern in Cambodia and regions where thiamine-poor white rice is a staple food. Low maternal thiamine intake reduces breast milk thiamine concentrations, placing breastfed infants at risk of beriberi. Objective: To determine if consumption of thiamine-fortified fish sauce yields higher erythrocyte thiamine diphosphate concentrations (eTDP) among lactating women and newborn infants and higher breast milk thiamine concentrations compared with a control sauce...
October 3, 2016: JAMA Pediatrics
Nicola Personeni, Marina Baretti, Silvia Bozzarelli, Paola Spaggiari, Luca Rubino, Maria Chiara Tronconi, Uberto Fumagalli Romario, Riccardo Rosati, Laura Giordano, Massimo Roncalli, Armando Santoro, Lorenza Rimassa
BACKGROUND: HER2 and topoisomerase 2 alpha (TOP2A) genomic status was previously reported to predict benefit from anthracyclines in breast cancer. We sought to define the prognostic impact and possible pitfalls related to these biomarkers in resectable gastroesophageal adenocarcinoma. METHODS: HER2 and TOP2A gene amplification by fluorescent in situ hybridization and HER2 protein expression by immunohistochemistry (IHC) were assessed on whole tissue sections from 101 patients receiving peri- or postoperative epirubicin-based chemotherapy...
August 16, 2016: Gastric Cancer
Huiping Li, Bin Shao, Yin Yan, Guohong Song, Xiaoran Liu, Jing Wang, Xu Liang
OBJECTIVE: To observe the efficacy and safety of trastuzumab combined with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing advanced breast cancer. METHODS: A total of 90 patients with HER2-overexpressing advanced breast cancer were enrolled in this study. All patients were diagnosed with ductal invasive breast cancer by pathological analysis, and were aged between 31-73 years with a median of 51 years. HER2-positivity was defined as 3(+) staining in immunochemistry or amplification of fluorescence in situ hybridization (FISH, ratio ≥2...
June 2016: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
Albina Stocker, Marie-Luise Hilbers, Claire Gauthier, Josias Grogg, Gerd A Kullak-Ublick, Burkhardt Seifert, Zsuzsanna Varga, Andreas Trojan
BACKGROUND: Adjuvant therapy comprising the HER2 receptor antagonist trastuzumab is associated with a significant improvement in disease-free and overall survival as compared to chemotherapy alone in localized HER2-positive breast cancer (BC). However, a subset of HER2-positive tumors seems to respond less favorably to trastuzumab. Various mechanisms have been proposed for trastuzumab resistance, such as high HER2 to Chromosome 17 FISH (HER2/CEP17) ratios and the possibility that single agent trastuzumab may not suffice to efficiently block HER2 downstream signaling thresholds...
2016: PloS One
Kazuki Moro, Masayuki Nagahashi, Rajesh Ramanathan, Kazuaki Takabe, Toshifumi Wakai
Inflammation is a central process in several disorders and contributes to cancer progression. Inflammation involves a complex cascade of pro-inflammatory and anti-inflammatory signaling events with protein and lipid mediators. Recent advances in lipid detection have revealed the importance of lipid mediators in inflammation. Omega three polyunsaturated fatty acids (ω-3 PUFA) are found naturally in fish oil and have been extensively studied in multiple inflammatory diseases with improved outcomes. Resolvins are thought to be the active metabolites of ω-3 PUFA, and are responsible for facilitating the resolving phase of acute inflammation...
July 16, 2016: World Journal of Clinical Cases
Christine Prell, Berthold Koletzko
BACKGROUND: Proper infant nutrition promotes healthy growth and development and lowers the risk of disease in later life. METHODS: This review is based on pertinent articles retrieved by a selective search, including guidelines, meta-analyses, and systematic reviews. RESULTS: Infants should be exclusively breast-fed until at least the age of 4 months. Infants who are no longer being breast-fed, or no longer exclusively so, should be given commercially available low-protein infant formula containing long-chain polyunsaturated fatty acids...
June 24, 2016: Deutsches Ärzteblatt International
Lei Guo, Wenbin Li, Xinxin Zhu, Yun Ling, Tian Qiu, Lin Dong, Yi Fang, Hongying Yang, Jianming Ying
PURPOSE: To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we evaluated the prevalence and significance of PD-L1 protein expression with a validated antibody and CD274 gene alternation in a large cohort of triple negative breast cancer (TNBC) and correlated with clinicopathological data and patients overall survival. METHODS: Immunohistochemistry and in situ mRNA hybridization was used to detect PD-L1 protein and mRNA expression in tumor tissues from 183 TNBC patients respectively...
2016: SpringerPlus
Lisa Oberauner-Wappis, Martina Loibner, Christian Viertler, Daniel Groelz, Ralf Wyrich, Kurt Zatloukal
Molecular diagnostics in personalized medicine increasingly relies on the combination of a variety of analytical technologies to characterize individual diseases and to select patients for targeted therapies. The gold standard for tissue-based diagnostics is fixation in formalin and embedding in paraffin, which results in excellent preservation of morphology but negatively impacts on a variety of molecular assays. The formalin-free, non-cross-linking PAXgene tissue system preserves morphology in a similar way to formalin, but also preserves biomolecules essentially in a similar way to cryopreservation, which markedly widens the spectrum, sensitivity and accuracy of molecular analytics...
April 2016: International Journal of Experimental Pathology
Nasrin Amirifard, Edris Sadeghi
BACKGROUND: Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all cancers in men and less than 1% of all diagnosed breast cancers. In this study, we retrospectively evaluated the clinicopathological features, treatment options and overall survival in Kurdish MBC cases. MATERIALS AND METHODS: Seventeen MBC were referred to Department of Radiation Oncology in Imam Reza Hospital, Kermanshah, Iran, between 2010 and 2016. Immunohistochemical analysis was performed for ER, PR and Her2 biomarkers and FISH for those with Her2 2+...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"